These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1145668)

  • 1. Aldosterone plasma radioimmunoassay interference by a spirolactone metabolite.
    Sadée W; Finn AM; Schmiedek P; Baethmann A
    Steroids; 1975 Mar; 25(3):301-11. PubMed ID: 1145668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Datta P; Dasgupta A
    Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A; Johnson MJ
    J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of canrenoate K on corticosteroid biosynthesis in nephrectomized dogs.
    Lasaridis AN; Tourkantonis A; Spanos P; Apostolopoulou K; Pharmakiotis A
    J Steroid Biochem; 1984 Apr; 20(4A):923-9. PubMed ID: 6323885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
    Dasgupta A; Johnson MJ; Sengupta TK
    J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of canrenoate-K and prorenoate-K upon aldosterone biosynthesis in perifused frog interrenal glands.
    Delarue C; Leboulenger F; Tonon MC; Jegou S; Leroux P; Kusmierek MC; Corvol P; Vaillant R; Vaudry H
    Steroids; 1979 Sep; 34(3):319-32. PubMed ID: 494369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue distribution of 3H-canrenoate potassium in rabbits.
    Finn AM; Brown R; Sadée W
    J Pharm Sci; 1977 Feb; 66(2):275-7. PubMed ID: 839430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of spironolactone and potassium canrenoate in humans.
    Kojima K; Yamamoto K; Fujioka H; Kaneko H
    J Pharmacobiodyn; 1985 Mar; 8(3):161-6. PubMed ID: 4009408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
    Casals-Stenzel J; Schmalbach J; Losert W
    Eur J Clin Pharmacol; 1977 Dec; 12(4):247-55. PubMed ID: 590311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous automated determination of spironolactone metabolites in serum.
    Neubert P; Koch K
    J Pharm Sci; 1977 Aug; 66(8):1131-4. PubMed ID: 894500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of some extra-renal effects of spironolactone and canrenone.
    Huston GJ; Al-Dujaili EA
    Br J Clin Pharmacol; 1979 Apr; 7(4):385-92. PubMed ID: 444357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
    van der Merwe PJ; Müller DG; Clark EC
    J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
    [No Abstract]   [Full Text] [Related]  

  • 20. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
    Dasgupta A; Saffer H; Wells A; Datta P
    J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.